You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-CD52 Monoclonal Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

B-cell Chronic Lymphocytic Leukemia Trial in Peking (Alemtuzumab)

Suspended
  • B-cell Chronic Lymphocytic Leukemia
  • Alemtuzumab
  • Peking, Beijing, China
    Peking University Cancer Hospital
Jun 15, 2022

Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)

Recruiting
  • Sickle Cell Disease
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jul 31, 2022

Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma Trial in United States (genetic, biological,

Active, not recruiting
  • Relapsed/Refractory Large B Cell Lymphoma
  • Relapsed/Refractory Follicular Lymphoma
  • ALLO-501
  • +3 more
  • Gilbert, Arizona
  • +7 more
May 25, 2022

Amputation, Wounds and Injuries, Amputation, Traumatic Trial in Baltimore (biological, drug, procedure)

Recruiting
  • Amputation
  • +7 more
  • Monoclonal Antibody (Humanized Anti-CD52)
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins University School of Medicine
Aug 23, 2022

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
Has Results
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • alemtuzumab
  • +2 more
  • Chicago, Illinois
  • +1 more
Dec 29, 2020

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Urologic Injuries, Genital Diseases, Male, Amputation Trial (procedure, biological, drug)

Withdrawn
  • Urologic Injuries
  • +2 more
  • Penile Transplant
  • +2 more
  • (no location specified)
Apr 9, 2021

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Primary Membranous Nephropathy Trial in Beijing (B007)

Not yet recruiting
  • Primary Membranous Nephropathy
  • Beijing, China
    Peking university first hospital
Dec 20, 2022

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia Trial in

Completed
Has Results
  • B-cell Chronic Lymphocytic Leukemia
  • +4 more
  • alemtuzumab
  • +9 more
  • Rochester, Minnesota
    Mayo Clinic
Jun 11, 2020

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

Recruiting
  • Non-Malignant Neoplasm
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Leukemia Trial (90-Yttrium-labelled anti-CD66 mAb)

Not yet recruiting
  • Leukemia
  • 90-Yttrium-labelled anti-CD66 monoclonal antibody
  • (no location specified)
Aug 16, 2022

Antibody-mediated Rejection Trial in Vienna, Berlin (Felzartamab, Placebo)

Recruiting
  • Antibody-mediated Rejection
  • Vienna, Austria
  • +1 more
Aug 23, 2022

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Type 1 Diabetes Trial in Vancouver (Frexalimab, Placebo, Insulin)

Recruiting
  • Type 1 Diabetes Mellitus
  • Vancouver, British Columbia, Canada
    Investigational Site Number : 1240001
Oct 31, 2023

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25

Not yet recruiting
  • The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
  • CD25 prophylaxis
  • (no location specified)
Jun 20, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023